Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover

被引:0
作者
J. Collette
O. Bruyère
J. M. Kaufman
R. Lorenc
D. Felsenberg
T. D. Spector
M. Diaz- Curiel
S. Boonen
J.-Y. Reginster
机构
[1] University of Liège,Department of Clinical Biology, Bone and Cartilage Markers Laboratory
[2] University of Liège,WHO Collaborating Centre for Public Health Aspect of Osteoarticular Disorders
[3] Ghent University Hospital,Department of Endocrinology and Unit for osteoporosis and Metabolic Bone Diseases
[4] The Child’s Health Center,Department of Biochemistry
[5] Free & Humboldt University,Charité Campus Benjamin Franklin, Centre of Muscle and Bone Research
[6] St Thomas’ Hospital Campus,Department of Twin Research and Genetic Epidemiology, Kings College London
[7] Jimenez Diaz Foundation,Division of Geriatric Medicine
[8] UZ Gasthuisberg,undefined
[9] CHU Liège,undefined
来源
Osteoporosis International | 2010年 / 21卷
关键词
Anti-fracture efficacy; Biochemical marker; Bone turnover; Osteoporosis; Strontium ranelate; Vertebral fracture;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:233 / 241
页数:8
相关论文
共 121 条
[11]  
Civitelli R(2004)Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate J Bone Miner Res 19 323-329
[12]  
Gonnelli S(2006)Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the Fracture Intervention Trial J Bone Miner Res 21 292-299
[13]  
Zachei F(2005)Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis J Bone Miner Res 20 962-970
[14]  
Gonnelli S(2006)Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover Bone 39 237-243
[15]  
Cepollaro C(2004)The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis New Engl J Med 350 459-468
[16]  
Pondrelli C(2005)Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study J Clin Endocrinol Metab 90 2816-2822
[17]  
Gonnelli S(2001)Mechanisms of action and therapeutic potential of strontium in bone Calcif Tissue Int 69 121-129
[18]  
Cepollaro C(2005)Strontium ranelate: a novel mode of action of optimizing bone formation and resorption Osteoporos Int 16 S7-S10
[19]  
Pondrelli C(2006)Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors J Bone Miner Res 21 536-542
[20]  
Iwamoto J(2008)Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia J Bone Miner Res 23 433-438